KEGG   DRUG: D09980Help
Entry
D09980                      Drug                                   

Name
Trastuzumab emtansine (genetical recombination) (JAN);
Trastuzumab emtansine (USAN/INN);
Ado-trastuzumab emtansine;
Kadcyla (TN)
Product
Formula
C6448H9948N1720O2012S44
Exact mass
145075.67
Mol weight
145165.1575
Activity
Treatment of cancer
Remark
Therapeutic category: 
ATC code: 
Drug group: 
Comment
antibody-drug conjugate/ACD (Trastuzumab [DR:D03257] conjugate to cytotoxic agent Mertansine [DR:D04864] analogue)
Target
ERBB2 tyrosine kinase (HER2) [HSA:2064] [KO:K05083]
  Pathway
hsa04012  ErbB signaling pathway
hsa04020  Calcium signaling pathway
hsa04510  Focal adhesion
hsa04520  Adherens junction
hsa05200  Pathways in cancer  
 
Interaction
Genomic biomarker: HER2 [HSA:2064]
Drug interaction
Structure map
Antineoplastics - protein kinases inhibitors
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC14 Trastuzumab emtansine
      D09980  Trastuzumab emtansine (genetical recombination) (JAN); Trastuzumab emtansine (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D09980  Trastuzumab emtansine (genetical recombination) (JAN); Trastuzumab emtansine (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cytokine receptors
  Receptor tyrosine kinase
   RTK class I (EGF receptor family)
    ERBB2 tyrosine kinase
     Trastuzumab
      D09980  Trastuzumab emtansine (USAN/INN)
Antineoplastics [BR:br08308]
 Molecularly targeted agents
  Monoclonal antibody
   Trastuzumab
    D09980  Trastuzumab emtansine (USAN/INN)
BRITE hierarchy
Other DBs
CAS: 
1018448-65-1
PubChem: 
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system